: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription

Articles published in J Neurol
Retrieve available abstracts of 444 articles:
HTML format

Single Articles

May 2024

BARDEL B, Creange A, Bonardet N, Bapst B, et al
Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
PubMed Abstract available

GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
PubMed Abstract available

PREZIOSA P, Rocca MA, Filippi M
Radiologically isolated syndromes: to treat or not to treat?
J Neurol. 2024;271:2370-2378.
PubMed Abstract available

LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al
Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective.
J Neurol. 2024;271:2824-2839.
PubMed Abstract available

KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al
Ravulizumab in myasthenic crisis: the first case report.
J Neurol. 2024;271:2898-2901.
PubMed

BURTON JM, Youn S, Al-Ani A, Costello F, et al
Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
J Neurol. 2024;271:2662-2671.
PubMed Abstract available

HEIDER D, Stetefeld H, Meisel A, Bosel J, et al
POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis.
J Neurol. 2024;271:2875-2879.
PubMed

RISI M, Greco G, Masciocchi S, Rigoni E, et al
MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
J Neurol. 2024;271:2840-2843.
PubMed Abstract available

DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al
Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
J Neurol. 2024;271:2866-2870.
PubMed Abstract available

ROCCA MA, Romano F, Tedone N, Filippi M, et al
Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
PubMed Abstract available

April 2024

DIMAURO KA, Swetlik C, Cohen JA
Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
PubMed Abstract available

ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
PubMed Abstract available

FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
PubMed

NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
PubMed Abstract available

SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
PubMed Abstract available

HIRT J, Dembowska K, Woelfle T, Axfors C, et al
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
PubMed Abstract available

SINGER BA, Feng J, Chiong-Rivero H
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
PubMed Abstract available

ZHANG Y, Liu D, Zhang Z, Huang X, et al
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
PubMed

STALTER J, Pars K, Witt K
Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
PubMed Abstract available

MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
PubMed Abstract available

CELIK M, Baba C, Irmak C, Ozakbas S, et al
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
PubMed Abstract available

STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
PubMed Abstract available

TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
Takotsubo cardiomyopathy in Guillain-Barre syndrome.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
PubMed Abstract available

MAIDA E, Moccia M, Palladino R, Borriello G, et al
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
PubMed Abstract available

SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
PubMed Abstract available

GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
PubMed

MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
J Neurol. 2024;271:1707-1716.
PubMed Abstract available

WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
J Neurol. 2024;271:1861-1872.
PubMed Abstract available

TEDONE N, Vizzino C, Meani A, Gallo A, et al
The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
J Neurol. 2024;271:1813-1823.
PubMed Abstract available

GLASER A, Butzkueven H, van der Walt A, Gray O, et al
Big Multiple Sclerosis Data network: an international registry research network.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
PubMed Abstract available

HUA T, Fan H, Duan Y, Tian D, et al
Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
PubMed Abstract available

March 2024

GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
PubMed Abstract available

SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
PubMed Abstract available

MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
PubMed Abstract available

ZHANG H, Ma J, Feng Y, Ma H, et al
Efgartigimod in the treatment of Guillain-Barre syndrome.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
PubMed Abstract available

FUCHS L, Shelly S, Vigiser I, Kolb H, et al
Real-World experience with efgartigimod in patients with myasthenia gravis.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
PubMed Abstract available

PILOTTO S, Floris M, Solla P, Pugliatti M, et al
Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
PubMed Abstract available

LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
PubMed

GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
PubMed Abstract available

ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
PubMed

VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
PubMed Abstract available

KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
PubMed Abstract available

HEGEN H, Berek K, Deisenhammer F, Berger T, et al
Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
PubMed Abstract available

HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
PubMed Abstract available

ZID Y, Robertson NP
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
PubMed

LI J, Wu X, Chu T, Tan X, et al
The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
PubMed Abstract available

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
PubMed Abstract available

February 2024

SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
PubMed Abstract available

TOLJAN K, Briggs FBS
Male sexual and reproductive health in multiple sclerosis: a scoping review.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
PubMed Abstract available

LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
PubMed Abstract available

VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
PubMed Abstract available

NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
PubMed

WEISS MD, Freimer M, Leite MI, Maniaol A, et al
Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
PubMed Abstract available

OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
PubMed

GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
PubMed Abstract available

CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
PubMed

BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
PubMed Abstract available

HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
Prodromal multiple sclerosis: considerations and future utility.
J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
PubMed Abstract available

VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
J Neurol. 2024;271:1019-1022.
PubMed

January 2024

BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
PubMed Abstract available

BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
PubMed Abstract available

NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
PubMed Abstract available

CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
PubMed Abstract available

FENG G, Posa S, Sureshkumar A, Simpson S, et al
Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
PubMed Abstract available

ZHENG P, Sandroff BM, Motl RW
Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
PubMed Abstract available

MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
PubMed

TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
PubMed Abstract available

LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
PubMed Abstract available

FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
J Neurol. 2024;271:75-78.
PubMed

NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
J Neurol. 2024;271:564-574.
PubMed Abstract available

WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
Neurological manifestation of HEV infection: still a rare disease entity?
J Neurol. 2024;271:386-394.
PubMed Abstract available

MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
J Neurol. 2024;271:374-385.
PubMed Abstract available

KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
J Neurol. 2024;271:141-176.
PubMed Abstract available

December 2023

AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
PubMed

LIU M, Ren H, Wang L, Fan S, et al
Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
PubMed Abstract available

ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
PubMed Abstract available

MISTRI D, Valsasina P, Storelli L, Filippi M, et al
Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
PubMed Abstract available

HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
PubMed Abstract available

COVEY TJ, Golan D, Sergott R, Wilken J, et al
Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
PubMed Abstract available

ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
PubMed Abstract available

TSAI CC, Jette S, Tremlett H
Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
PubMed Abstract available

November 2023

MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
PubMed Abstract available

MISTRI D, Tedone N, Biondi D, Vizzino C, et al
Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
PubMed Abstract available

JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
PubMed Abstract available

BISECCO A, Matrone F, Capobianco M, De Luca G, et al
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
PubMed Abstract available

SUN Y, Li G, Liu X, Zhao X, et al
Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
PubMed Abstract available

KENNEDY PGE, George W, Yu X
The elusive nature of the oligoclonal bands in multiple sclerosis.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
PubMed Abstract available

DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
PubMed Abstract available

FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
J Neurol. 2023;270:5392-5397.
PubMed Abstract available

JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
PubMed

October 2023

MANTERO V, Cordano C, Balgera R, Basilico P, et al
Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
PubMed

KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
PubMed Abstract available

DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
PubMed Abstract available

RIVEL M, Achiron A, Stern Y, Zeilig G, et al
Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
PubMed Abstract available

ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
Identification and management of subclinical disease activity in early multiple sclerosis: a review.
J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
PubMed Abstract available

ZINGANELL A, Gobel G, Berek K, Hofer B, et al
Multiple sclerosis in the elderly: a retrospective cohort study.
J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
PubMed Abstract available

SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
Multiple sclerosis: time for early treatment with high-efficacy drugs.
J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
PubMed Abstract available

RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
PubMed Abstract available

MANZANO GS, McEntire C, Venna N
Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
PubMed

ZHANG Z, Wang Z, Du X, Huang X, et al
Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
PubMed

KRAKER JA, Chen JJ
An update on optic neuritis.
J Neurol. 2023;270:5113-5126.
PubMed Abstract available

BRISCA G, Marini C, Buratti S, Mariani M, et al
Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
J Neurol. 2023;270:5034-5047.
PubMed Abstract available

WANG R, Sun D, Du Q, Shi Z, et al
Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
J Neurol. 2023;270:5085-5089.
PubMed

September 2023

RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
PubMed Abstract available

LI Y, Saul A, Taylor B, Ponsonby AL, et al
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
PubMed Abstract available

KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
PubMed Abstract available

WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
PubMed Abstract available

FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
PubMed Abstract available

GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
PubMed Abstract available

MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
PubMed

DI STEFANO V, Alonge P, Rini N, Militello M, et al
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
PubMed Abstract available

JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
PubMed Abstract available

MCCOMBE JA, Klassen BT, Flanagan EP, Teener JW, et al
Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome.
J Neurol. 2023;270:4555-4557.
PubMed

NAKAMURA N, Ishikawa H, Matsuyama H, Shindo A, et al
Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation.
J Neurol. 2023;270:4529-4532.
PubMed

August 2023

FERRAND M, Epstein J, Soudant M, Guillemin F, et al
Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
PubMed Abstract available

BONACCHI R, Valsasina P, Pagani E, Meani A, et al
Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
PubMed Abstract available

TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
PubMed Abstract available

JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
Cortical thickness and cognition in older people with multiple sclerosis.
J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
PubMed Abstract available

KUDO A, Yaguchi H, Tanaka K, Kimura A, et al
A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
J Neurol. 2023 Aug 23. doi: 10.1007/s00415-023-11946.
PubMed Abstract available

GOERTZEN A, Altawashi AK, Rieck J, Veh RW, et al
Autoimmune processes in neurological patients are much more common than presently suspected.
J Neurol. 2023 Aug 21. doi: 10.1007/s00415-023-11901.
PubMed Abstract available

CHANSON JB, Bouhour F, Aube-Nathier AC, Mallaret M, et al
Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.
J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11925.
PubMed Abstract available

SPIERER R, Lavi I, Bloch S, Mazar M, et al
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
PubMed Abstract available

KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
Multiple sclerosis lesions that impair memory map to a connected memory circuit.
J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
PubMed Abstract available

AL-ANI A, Chen JJ, Costello F
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
J Neurol. 2023;270:4132-4150.
PubMed Abstract available

July 2023

MAHMOOD A, Hawken J, Robertson NP
Clinical trials in myasthenia gravis.
J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11903.
PubMed

QIN M, Chen J, Guo X, Xiang X, et al
Movement disorders in autoimmune encephalitis: an update.
J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11881.
PubMed Abstract available

ROEBEN B, Scharf M, Miske R, Teegen B, et al
Seroprevalence of autoimmune antibodies in degenerative ataxias: a broad, disease-controlled screening in 456 subjects.
J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11900.
PubMed

TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
PubMed

NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
PubMed Abstract available

ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
PubMed Abstract available

LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
PubMed

PETROU P, Achiron A, Cohen EG, Garty M, et al
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Groupâ€ Viewpoint.
J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
PubMed Abstract available

AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
PubMed Abstract available

NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
PubMed Abstract available

MOOG TM, Smith AD, Burgess KW, McCreary M, et al
High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder.
J Neurol. 2023;270:3595-3602.
PubMed Abstract available

JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
J Neurol. 2023;270:3341-3368.
PubMed Abstract available

LUMSDEN DE, Lim M, Irani S
Letter to the editors: comment on "Status dystonicus in adult patients with anti-N-methyl-D-asparate-acid receptor encephalitis".
J Neurol. 2023;270:3630-3631.
PubMed

TEZUKA T, Okuzumi S, Nakashima C, Ide T, et al
Dysautonomia associated with immune checkpoint inhibitors.
J Neurol. 2023;270:3413-3423.
PubMed Abstract available

June 2023

RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
The added value of spinal cord lesions to disability accrual in multiple sclerosis.
J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
PubMed Abstract available

TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
PubMed Abstract available

LIANG Y, Wang G, Li B, Li G, et al
Autoimmune glial fibrillary acidic protein astrocytosis mimicking tuberculous meningitis: a retrospective study.
J Neurol. 2023 Jun 20. doi: 10.1007/s00415-023-11818.
PubMed Abstract available

ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
PubMed Abstract available

KRIEF N, Gabriel R, Cauquil C, Adams D, et al
Clinical features and maternal and fetal outcomes in women with Guillain-Barre syndrome in pregnancy.
J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11808.
PubMed Abstract available

GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
PubMed Abstract available

CHOMPOOPONG P, Rezk M, Mirman I, Berini SE, et al
TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11798.
PubMed Abstract available

MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
PubMed

HTET ZM, Tallantyre E
Optic neuritis and MOGAD.
J Neurol. 2023;270:3278-3279.
PubMed

HOLTZER R, Choi J, Motl RW, Foley FW, et al
Individual reserve in aging and neurological disease.
J Neurol. 2023;270:3179-3191.
PubMed Abstract available

YIN Z, Qiu Y, Duan A, Fang T, et al
Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
J Neurol. 2023;270:2950-2963.
PubMed Abstract available

ROSSI S, Gelsomino F, Rinaldi R, Muccioli L, et al
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
J Neurol. 2023;270:2975-2986.
PubMed Abstract available

May 2023

LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
PubMed Abstract available

AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
PubMed Abstract available

ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
PubMed

LIU B, Hu J, Sun C, Qiao K, et al
Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11759.
PubMed Abstract available

MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
J Neurol. 2023;270:2559-2566.
PubMed Abstract available

ZHANG Y, Cui L, Chen W, Huang H, et al
Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.
J Neurol. 2023;270:2693-2701.
PubMed Abstract available

DENG Z, Wang H, Huang K, Li Y, et al
Association between vascular risk factors and idiopathic normal pressure hydrocephalus: a Mendelian randomization study.
J Neurol. 2023;270:2724-2733.
PubMed Abstract available

April 2023

VARLEY JA, Strippel C, Handel A, Irani SR, et al
Autoimmune encephalitis: recent clinical and biological advances.
J Neurol. 2023 Apr 28. doi: 10.1007/s00415-023-11685.
PubMed Abstract available

VOGRIG A, Versace S, Gigli GL, Fabris M, et al
Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination.
J Neurol. 2023 Apr 28:1-5. doi: 10.1007/s00415-023-11723.
PubMed

KREMMYDA O, Feil K, Bardins S, Strupp M, et al
Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
PubMed

MEISEL A, Annane D, Vu T, Mantegazza R, et al
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11699.
PubMed Abstract available

VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
PubMed Abstract available

GILHUS NE
Myasthenia gravis, respiratory function, and respiratory tract disease.
J Neurol. 2023 Apr 26:1-12. doi: 10.1007/s00415-023-11733.
PubMed Abstract available

MARGONI M, Pagani E, Preziosa P, Gueye M, et al
Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
PubMed Abstract available

KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
Autonomic nervous system disorders in multiple sclerosis.
J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
PubMed Abstract available

MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
PubMed Abstract available

GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
PubMed Abstract available

GADOTH A, Devine MF, Pittock SJ, McKeon A, et al
Sleep disturbances associated with DPPX autoantibodies: a case series.
J Neurol. 2023 Apr 7. doi: 10.1007/s00415-023-11698.
PubMed Abstract available

YEO T, Siew RWE, Gulam MY, Tye JSN, et al
COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
PubMed Abstract available

ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
PubMed Abstract available

VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
J Neurol. 2023;270:2271-2282.
PubMed Abstract available

LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
J Neurol. 2023;270:2329-2332.
PubMed Abstract available

GHOLIZADEH S, Exuzides A, Lewis KE, Palmer C, et al
Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.
J Neurol. 2023;270:2048-2058.
PubMed Abstract available

ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
J Neurol. 2023;270:2042-2047.
PubMed Abstract available

HIEKE A, Spenner M, Schmitz F, Schumacher A, et al
The impact of the SARS-CoV-2-pandemic on patients with chronic inflammatory neuropathies: results from the German INHIBIT register.
J Neurol. 2023;270:1815-1822.
PubMed Abstract available

NEHME A, Lanthier S, Boulanger M, Aouba A, et al
Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices.
J Neurol. 2023;270:1989-1998.
PubMed Abstract available

March 2023

PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
PubMed Abstract available

TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
PubMed Abstract available

ROMANO F, Motl RW, Valsasina P, Amato MP, et al
Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
PubMed Abstract available

DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
PubMed

MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
PubMed Abstract available

VU T, Ortiz S, Katsuno M, Annane D, et al
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11617.
PubMed Abstract available

VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
PubMed Abstract available

LI G, You Q, Hou X, Zhang S, et al
The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
PubMed Abstract available

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
PubMed Abstract available

BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
PubMed Abstract available

TAKAI K, Endo T, Seki T, Inoue T, et al
Congestive myelopathy due to craniocervical junction arteriovenous fistulas mimicking transverse myelitis: a multicenter study on 27 cases.
J Neurol. 2023;270:1745-1753.
PubMed Abstract available

VABANESI M, Pinto AL, Vogrig A, Goncalves D, et al
SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.
J Neurol. 2023;270:1691-1701.
PubMed Abstract available

DIETMANN AS, Kruse N, Stork L, Gloth M, et al
Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
J Neurol. 2023;270:1416-1429.
PubMed Abstract available

NGUYEN TT, Kang JJ, Chae JH, Lee E, et al
Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis.
J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11611.
PubMed Abstract available

SCHEGK E, Beiser I, Achtnichts L, Nedeltchev K, et al
Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years.
J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11632.
PubMed

February 2023

BAETGE SJ, Filser M, Renner A, Raithel LM, et al
Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
PubMed Abstract available

MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
PubMed Abstract available

DIXON L, Colquhoun M, Taylor E, Carlucci F, et al
Orbital giant cell arteritis: two cases of bilateral orbital inflammation and arterial diffusion restriction on MRI.
J Neurol. 2023 Feb 11. doi: 10.1007/s00415-023-11593.
PubMed

SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
J Neurol. 2023;270:1178-1186.
PubMed Abstract available

HUANG L, Wang Y, Zhang R
Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
J Neurol. 2023;270:759-768.
PubMed Abstract available

FIONDA L, Lauletta A, Leonardi L, Perez JA, et al
Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.
J Neurol. 2023;270:960-974.
PubMed Abstract available

GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
J Neurol. 2023;270:1135-1140.
PubMed Abstract available

MAGRO G, Barone S, Tosto F, De Martino A, et al
Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
J Neurol. 2023;270:595-600.
PubMed Abstract available

January 2023

MINAMINO M, Miyamoto K, Kuwahara M, Yoshikawa K, et al
Characteristics of Guillain-Barre syndrome in super-elderly individuals.
J Neurol. 2023 Jan 16. doi: 10.1007/s00415-023-11567.
PubMed Abstract available

CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
PubMed Abstract available

SACCA F, Barnett C, Vu T, Peric S, et al
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
J Neurol. 2023 Jan 4. doi: 10.1007/s00415-022-11517.
PubMed Abstract available

LEE SU, Baek SH, Kim HJ, Choi JY, et al
Acute comitant strabismus in anti-GQ1b antibody syndrome.
J Neurol. 2023;270:486-492.
PubMed Abstract available

HAGEBOUTROS K, Hattiangadi Thomas N, Hutchinson M, Banwell B, et al
Neuropsychological functioning in children and adolescents with anti-NMDA receptor encephalitis (anti-NMDARE).
J Neurol. 2023;270:402-412.
PubMed Abstract available

YANG S, Zhang C, Zhang TX, Feng B, et al
A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.
J Neurol. 2023;270:348-356.
PubMed Abstract available

DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
J Neurol. 2023;270:240-249.
PubMed Abstract available

December 2022

BARBAGALLO M, Straumann D, Binaghi E, Schmick A, et al
A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection.
J Neurol. 2022 Dec 28:1-5. doi: 10.1007/s00415-022-11548.
PubMed

PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
PubMed

TIERNEY P, Zekeridou A, Adam O
Phosphodiesterase 10A autoimmunity presenting as cerebellar ataxia responsive to plasma exchange: a case report.
J Neurol. 2022 Dec 26. doi: 10.1007/s00415-022-11542.
PubMed

LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
PubMed Abstract available

SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
PubMed Abstract available

ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
PubMed Abstract available

GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
PubMed Abstract available

MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
J Neurol. 2022;269:6504-6511.
PubMed Abstract available

PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
J Neurol. 2022;269:6366-6376.
PubMed Abstract available

November 2022

SIMPSON R, Posa S, Bruno T, Simpson S, et al
Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
PubMed Abstract available

PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
PubMed Abstract available

FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
PubMed Abstract available

MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
PubMed Abstract available

KWON YN, Woodhall M, Sung JJ, Kim KK, et al
Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis.
J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11458.
PubMed Abstract available

KIM S, Kim KH, Chung HY, Park HJ, et al
Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.
J Neurol. 2022 Nov 16. pii: 10.1007/s00415-022-11485.
PubMed Abstract available

PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
PubMed Abstract available

GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
PubMed Abstract available

DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
PubMed Abstract available

SIMPSON R, Posa S, Langer L, Bruno T, et al
A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
PubMed Abstract available

TERESHKO Y, Gigli GL, Pez S, De Pellegrin A, et al
New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11472.
PubMed Abstract available

NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
Health-related quality of life in Japanese patients with multiple sclerosis.
J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
PubMed Abstract available

KURI A, Vickaryous N, Awad A, Jacobs BM, et al
Vitamin D genetic risk scores in multiple sclerosis.
J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
PubMed Abstract available

JARIUS S, Haas J, Wildemann B
Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis.
J Neurol. 2022 Nov 4. pii: 10.1007/s00415-022-11417.
PubMed

STRANO CMM, Sorrenti B, Bosco L, Falzone YM, et al
Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
J Neurol. 2022;269:6152-6154.
PubMed

October 2022

OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
PubMed Abstract available

WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
PubMed Abstract available

PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
PubMed Abstract available

COSTELLO F, Burton JM
Contemporary management challenges in seropositive NMOSD.
J Neurol. 2022;269:5674-5681.
PubMed Abstract available

KANG L, Wan C
Paraneoplastic syndrome in neuroophthalmology.
J Neurol. 2022;269:5272-5282.
PubMed Abstract available

LEVI-STRAUSS J, Provost C, Wane N, Jacquemont T, et al
NMOSD typical brain lesions after COVID-19 mRNA vaccination.
J Neurol. 2022;269:5213-5215.
PubMed

KOCH MW, Mostert J, Repovic P, Bowen JD, et al
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
J Neurol. 2022;269:5319-5327.
PubMed Abstract available

September 2022

ZHANG S, Yang S, Lu J, Liu S, et al
CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review.
J Neurol. 2022 Sep 30. pii: 10.1007/s00415-022-11369.
PubMed Abstract available

STASCHEIT F, Grittner U, Hoffmann S, Mergenthaler P, et al
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
J Neurol. 2022 Sep 27. pii: 10.1007/s00415-022-11389.
PubMed Abstract available

MARGONI M, Pagani E, Preziosa P, Palombo M, et al
In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
PubMed Abstract available

PAGANI E, Storelli L, Pantano P, Petsas N, et al
Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
PubMed Abstract available

FILIPPI M, Amato MP, Centonze D, Gallo P, et al
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
PubMed

FILSER M, Buchner A, Fink GR, Gold SM, et al
The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
PubMed Abstract available

CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
PubMed Abstract available

REYES-VEGA MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, et al
Clinical features of Guillain-Barre syndrome and factors associated with mortality during the 2019 outbreak in Peru.
J Neurol. 2022 Sep 13. pii: 10.1007/s00415-022-11331.
PubMed Abstract available

NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
PubMed

MAIER A, Kapfenberger R, Katona I, Weis J, et al
Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.
J Neurol. 2022 Sep 9. pii: 10.1007/s00415-022-11340.
PubMed Abstract available

CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
PubMed Abstract available

August 2022

WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
PubMed Abstract available

GUEGUEN A, Hijazi B, Zuber K, Deschamps R, et al
Generalization of ocular myasthenia gravis 10 years after onset.
J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11316.
PubMed Abstract available

BARNAY M, Duval F, Sole G, Carla L, et al
Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
J Neurol. 2022 Aug 22. pii: 10.1007/s00415-022-11345.
PubMed Abstract available

LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
Correction to: Burden of disease in myasthenia gravis: taking the patient's perspective.
J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11290.
PubMed

JAFARPOUR S, Banerjee A, Boyd NK, Vogel BN, et al
Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.
J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11325.
PubMed Abstract available

FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
PubMed Abstract available

KREFT KL, Robertson NP
Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
PubMed

July 2022

DORON A, Piura Y, Vigiser I, Kolb H, et al
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
J Neurol. 2022 Jul 30. pii: 10.1007/s00415-022-11303.
PubMed Abstract available

CAPUANO R, Altieri M, Conte M, Bisecco A, et al
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
PubMed Abstract available

BLACKMAN G, Lim MF, Pollak T, Al-Diwani A, et al
The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data.
J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11224.
PubMed Abstract available

MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
PubMed Abstract available

TAN X, Liu Y, Wu X, Guo Y, et al
Guillain-Barre-like syndrome: an uncommon feature of CASPR2 and LGI1 autoimmunity.
J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11248.
PubMed Abstract available

EID K, Torkildsen O, Aarseth J, Celius EG, et al
Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
PubMed Abstract available

MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
Seronegative myasthenic crisis: a multicenter analysis.
J Neurol. 2022;269:3904-3911.
PubMed Abstract available

ALCALA C, Cubas L, Carratala S, Gascon F, et al
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
J Neurol. 2022;269:3495-3500.
PubMed Abstract available

June 2022

CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
PubMed Abstract available

SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
PubMed

LEGUY S, Lefort M, Lescot L, Michaud A, et al
COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
PubMed Abstract available

SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
PubMed Abstract available

DORCET G, Migne H, Biotti D, Bost C, et al
Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
PubMed Abstract available

ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
Neuroimmune disorders in COVID-19.
J Neurol. 2022;269:2827-2839.
PubMed Abstract available

YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
Bedside and laboratory diagnostic testing in myasthenia.
J Neurol. 2022;269:3372-3384.
PubMed Abstract available

LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
J Neurol. 2022;269:3359-3362.
PubMed

JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
J Neurol. 2022;269:2850-2853.
PubMed

AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
J Neurol. 2022;269:3175-3179.
PubMed Abstract available

VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
J Neurol. 2022;269:3159-3166.
PubMed Abstract available

ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
J Neurol. 2022;269:3276-3285.
PubMed Abstract available

AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
J Neurol. 2022;269:3136-3146.
PubMed Abstract available

DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
J Neurol. 2022;269:3129-3135.
PubMed Abstract available

MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
PubMed Abstract available

May 2022

HRASTELJ J, Robertson NP
A role for the Epstein-Barr virus in multiple sclerosis aetiology?
J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
PubMed

GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
PubMed Abstract available

JARIUS S, Komorowski L, Regula JU, Haas J, et al
Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
PubMed Abstract available

WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
PubMed

FILIPPI M, Amato MP, Centonze D, Gallo P, et al
Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
PubMed Abstract available

BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
Patients with multiple sclerosis: a burden and cost of illness study.
J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
PubMed Abstract available

SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
PubMed Abstract available

HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
Age-specific effects of childhood body mass index on multiple sclerosis risk.
J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
PubMed Abstract available

SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
PubMed Abstract available

GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
PubMed Abstract available

SANSONE G, Bonifati DM
Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
PubMed Abstract available

KIM H, Fraser S
Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
J Neurol. 2022;269:2378-2402.
PubMed Abstract available

GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
J Neurol. 2022;269:2293-2300.
PubMed Abstract available

WEISS D, Cantre D, Zettl UK, Storch A, et al
Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
J Neurol. 2022;269:2778-2780.
PubMed

HIROSE S, Hara M, Kamei S, Dalmau J, et al
Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
J Neurol. 2022;269:2486-2492.
PubMed Abstract available

April 2022

HVID LG, Stenager E, Dalgas U
Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
PubMed Abstract available

EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
PubMed Abstract available

DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
PubMed Abstract available

ZHANG Y, Yin H, Zhang D, Xu Y, et al
Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
PubMed Abstract available

WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
PubMed Abstract available

STORELLI L, Pagani E, Meani A, Preziosa P, et al
Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
PubMed Abstract available

CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
Time course of lesion-induced atrophy in multiple sclerosis.
J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
PubMed Abstract available

MOOG TM, McCreary M, Wilson A, Stanley T, et al
Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
PubMed Abstract available

BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
PubMed

VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
PubMed Abstract available

FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
J Neurol. 2022;269:1758-1763.
PubMed Abstract available

ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
J Neurol. 2022;269:2073-2079.
PubMed Abstract available

ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
J Neurol. 2022;269:1786-1801.
PubMed Abstract available

MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
J Neurol. 2022;269:1996-2003.
PubMed Abstract available

March 2022

DEANA C, Bagatto D, Battezzi A, Pecori D, et al
Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
PubMed

BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
PubMed

WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
PubMed Abstract available

ALLMAN M, Tallantyre E, Robertson NP
Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
PubMed

MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
PubMed Abstract available

DU Y, Li C, Hao YF, Zhao C, et al
Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
PubMed Abstract available

MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
PubMed Abstract available

ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
PubMed Abstract available

KUBICKI K, Grzybowski A
Pioneers in neurology: Charles Miller Fisher (1913-2012).
J Neurol. 2022;269:1727-1729.
PubMed

KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
Natalizumab-induced pneumonitis.
J Neurol. 2022;269:1688-1690.
PubMed

KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
J Neurol. 2022;269:1121-1132.
PubMed Abstract available

WANG Y, Wang Y, Huo L, Li Q, et al
SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
J Neurol. 2022;269:1071-1092.
PubMed Abstract available

KOCH MW, Mostert J, Repovic P, Bowen JD, et al
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
J Neurol. 2022;269:1663-1669.
PubMed Abstract available

XIE H, Shao Y, Du J, Song Y, et al
Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
J Neurol. 2022;269:1641-1650.
PubMed Abstract available

NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
J Neurol. 2022;269:1618-1630.
PubMed Abstract available

CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
Application of deep-learning to the seronegative side of the NMO spectrum.
J Neurol. 2022;269:1546-1556.
PubMed Abstract available

HU J, Sun C, Lu J, Zhao C, et al
Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
J Neurol. 2022;269:1250-1263.
PubMed Abstract available

BONACCHI R, Meani A, Pagani E, Marchesi O, et al
The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
PubMed Abstract available

February 2022

COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
PubMed

BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
PubMed Abstract available

RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
PubMed Abstract available

CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
PubMed Abstract available

SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
Neurologic manifestations of giant cell arteritis.
J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
PubMed Abstract available

ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
PubMed Abstract available

ISMAIL II, Salama S
Association of CNS demyelination and COVID-19 infection: an updated systematic review.
J Neurol. 2022;269:541-576.
PubMed Abstract available

PATZIG M, Forbrig R, Kupper C, Eren O, et al
Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
J Neurol. 2022;269:982-996.
PubMed Abstract available

BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
J Neurol. 2022;269:836-845.
PubMed Abstract available

SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
J Neurol. 2022;269:907-912.
PubMed Abstract available

BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
J Neurol. 2022;269:945-955.
PubMed Abstract available

LANDI D, Signori A, Cellerino M, Fenu G, et al
What happens after fingolimod discontinuation? A multicentre real-life experience.
J Neurol. 2022;269:796-804.
PubMed Abstract available

January 2022

VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
PubMed Abstract available

PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
PubMed Abstract available

GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
PubMed Abstract available

PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
PubMed Abstract available

BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
PubMed

MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
PubMed Abstract available

COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
PubMed Abstract available

CRUZ RA, Varkey T, Flavia A, Samways APA, et al
Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
PubMed Abstract available

KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
PubMed Abstract available

PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
PubMed Abstract available

BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
PubMed Abstract available

THOMAS R, Wynford-Thomas R, Robertson NP
Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
PubMed

TALAEI M, Robertson NP
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
J Neurol. 2022;269:534-536.
PubMed

ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
J Neurol. 2022;269:461-467.
PubMed Abstract available

XU J, Guo Y, Li J, Lv X, et al
Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
J Neurol. 2022;269:389-398.
PubMed Abstract available

HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
J Neurol. 2022;269:49-54.
PubMed

DE LOTT LB, Bennett JL, Costello F
The changing landscape of optic neuritis: a narrative review.
J Neurol. 2022;269:111-124.
PubMed Abstract available

December 2021

LEGUY S, Le Page E, Drapier S
Elderly onset neuromyelitis optica spectrum disorder: a case report.
J Neurol. 2021;268:4897-4898.
PubMed

SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
J Neurol. 2021;268:4448-4478.
PubMed Abstract available

KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
J Neurol. 2021;268:4824-4833.
PubMed Abstract available

FLANAGAN EP
Paraneoplastic disorders of the nervous system.
J Neurol. 2021;268:4899-4907.
PubMed Abstract available

CABAL-HERRERA AM, Mateen FJ
COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
J Neurol. 2021;268:4479-4482.
PubMed

SIRITHO S, Nopsopon T, Pongpirul K
Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
J Neurol. 2021;268:4549-4562.
PubMed Abstract available

HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
J Neurol. 2021;268:4522-4536.
PubMed Abstract available

November 2021

KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
PubMed Abstract available

ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
PubMed Abstract available

RIO J, Rovira A, Gasperini C, Tintore M, et al
Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
PubMed

LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
PubMed Abstract available

SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
PubMed Abstract available

LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
Burden of disease in myasthenia gravis: taking the patient's perspective.
J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
PubMed Abstract available

CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.
PubMed

MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
J Neurol. 2021;268:3995-3997.
PubMed

October 2021

FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
Functional network dynamics and decreased conscientiousness in multiple sclerosis.
J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
PubMed Abstract available

WASHINGTON F, Langdon D
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
PubMed Abstract available

ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
PubMed Abstract available

BURT RK, Han X, Quigley K, Helenowski IB, et al
Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
PubMed Abstract available

FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
PubMed Abstract available

PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
PubMed Abstract available

AL-ANSARI A, Robertson NP
Autoimmune encephalitis: clinical presentation, investigation and treatment.
J Neurol. 2021;268:3935-3937.
PubMed

FUKAMI Y, Iijima M, Koike H, Yamada S, et al
Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
J Neurol. 2021;268:3835-3844.
PubMed Abstract available

JARIUS S, Wilken D, Haas J, Ruprecht K, et al
Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
J Neurol. 2021;268:3758-3765.
PubMed Abstract available

QUEROL L, Crabtree M, Herepath M, Priedane E, et al
Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
J Neurol. 2021;268:3706-3716.
PubMed Abstract available

RIO J, Rovira A, Gasperini C, Tintore M, et al
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
PubMed Abstract available

September 2021

AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.
PubMed

PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
PubMed Abstract available

PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
PubMed Abstract available

BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
PubMed Abstract available

BERCIANO J
Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
PubMed

ANDERSEN MA, Buron MD, Magyari M
Late-onset MS is associated with an increased rate of reaching disability milestones.
J Neurol. 2021;268:3352-3360.
PubMed Abstract available

HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
J Neurol. 2021;268:3125-3128.
PubMed Abstract available

VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
J Neurol. 2021;268:3129-3131.
PubMed

August 2021

SUN J, Xie Y, Wang Q, Shen J, et al
Genes associated with grey matter volume reduction in multiple sclerosis.
J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
PubMed Abstract available

BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
Identifying falls remotely in people with multiple sclerosis.
J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
PubMed Abstract available

MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
PubMed Abstract available

ALVINO B, Arianna F, Assunta B, Antonio C, et al
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
PubMed Abstract available

PARDO G, Coates S, Okuda DT
Outcome measures assisting treatment optimization in multiple sclerosis.
J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
PubMed Abstract available

FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
J Neurol. 2021;268:3011-3019.
PubMed Abstract available

CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
J Neurol. 2021;268:2895-2899.
PubMed Abstract available

CILINGIR V, Batur M
First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
J Neurol. 2021;268:2858-2865.
PubMed Abstract available

WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
J Neurol. 2021;268:2700-2702.
PubMed

July 2021

O SULLIVAN C, Zach F, Moser T, Pilz G, et al
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.
PubMed

FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
PubMed Abstract available

RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
PubMed Abstract available

NIESSEN A, Schwarz B, Urban M, Kramer S, et al
Aseptic meningitis after glatiramer acetate.
J Neurol. 2021;268:2589-2590.
PubMed

STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
Sneddon syndrome: a comprehensive clinical review of 53 patients.
J Neurol. 2021;268:2450-2457.
PubMed Abstract available

MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
J Neurol. 2021;268:2327-2330.
PubMed Abstract available

June 2021

CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
PubMed Abstract available

SANKARI SE, Van Essche C, van Pesch V
Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
PubMed

KOGEL AK, Gold R, Schneider R
CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
PubMed

S G, S L, C Z, A N, et al
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
PubMed Abstract available

HANNINEN K, Viitala M, Atula S, Laakso SM, et al
Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
PubMed Abstract available

HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
PubMed

KIM SH, Baek SH, Lee SU, Yu S, et al
Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
J Neurol. 2021;268:2263-2266.
PubMed

DAO LM, Machule ML, Bacher P, Hoffmann J, et al
Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
J Neurol. 2021;268:2123-2131.
PubMed Abstract available

LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
Bickerstaff encephalitis after COVID-19.
J Neurol. 2021;268:2035-2037.
PubMed

May 2021

JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
PubMed Abstract available

CHEN MH, Chiaravalloti ND, DeLuca J
Neurological update: cognitive rehabilitation in multiple sclerosis.
J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
PubMed Abstract available

HOU Y, Shao K, Yan Y, Dai T, et al
Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
PubMed Abstract available

KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
PubMed

ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
PubMed Abstract available

HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
PubMed Abstract available

TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
PubMed Abstract available

RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
PubMed Abstract available

THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
J Neurol. 2021;268:1818-1826.
PubMed Abstract available

April 2021

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
PubMed Abstract available

COVEY TJ, Golan D, Doniger GM, Sergott R, et al
Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
PubMed Abstract available

CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
PubMed Abstract available

WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
PubMed Abstract available

NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
PubMed Abstract available

URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
J Neurol. 2021;268:1536-1539.
PubMed

KAPOOR M, Keh R, Compton L, Morrow S, et al
Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
J Neurol. 2021;268:1485-1490.
PubMed Abstract available

NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
J Neurol. 2021;268:1419-1433.
PubMed Abstract available

CHAUDHARY UJ, Rajabally YA
Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
J Neurol. 2021;268:1366-1373.
PubMed Abstract available

March 2021

VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
J Neurol. 2021;268:978-988.
PubMed Abstract available

MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
J Neurol. 2021;268:879-890.
PubMed Abstract available

February 2021

YOO JS, Kim YS, Kim HY, Kwon HS, et al
Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
PubMed Abstract available

MARTIN T, Duke S, Kumar V, Fadhil A, et al
NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
J Neurol. 2021;268:714-716.
PubMed

SCHROTER N, Weiller C, Rauer S, Waller CF, et al
Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
J Neurol. 2021;268:709-711.
PubMed

OKADA K, Seki M, Yaguchi H, Sakuta K, et al
Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
J Neurol. 2021;268:680-688.
PubMed Abstract available

BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
J Neurol. 2021;268:651-657.
PubMed Abstract available

January 2021

STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
J Neurol. 2021;268:367-376.
PubMed Abstract available

KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
J Neurol. 2021;268:265-275.
PubMed Abstract available

July 2020

BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
J Neurol. 2020;267:2101-2114.
PubMed Abstract available

MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
J Neurol. 2020;267:1906-1911.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.